HarrisMartin's Pharmaceutical Antitrust Litigation Conference: Generic Drugs & Emerging Price-Fixing Cases Speaker Profiles



Co-Chair Dianne M. Nast, NastLaw LLC, Philadelphia Show/Hide Bio

Co-Chair Dianne M. Nast

Dianne Nast has extensive and diverse experience in pharmaceutical litigation and antitrust litigation, and much of her professional career has been dominated by this type of litigation. With over 25 years in this field, she is consistently recognized by her clients and peers as one of the best lawyers in the country.

The National Law Journal selected Ms. Nast as one of the nation’s top fifty women litigators. She has been included in The Best Lawyers in America since 2003, and she has repeatedly been named by Philadelphia Magazine as one of Pennsylvania’s top fifty women attorneys. She has been selected as a Super Lawyer every year for more than a decade, and has earned an AV rating in the prestigious Martindale Hubbell lawyer rankings.

Co-Chair Thomas M. Sobol , Hagens Berman Sobol Shapiro LLP, Boston Show/Hide Bio

Co-Chair Thomas M. Sobol

• Partner & Executive Committee Member, Hagens Berman Sobol Shapiro
• Leads Hagens Berman’s Boston office
• Leader in drug pricing litigation efforts against numerous pharmaceutical and medical device companies
• Lead negotiator in court-approved settlements totaling more than $2 billion
• Currently court-appointed lead counsel for In re Skelaxin Antitrust Litigation, In re Nexium Antitrust Litigation, In re Lipitor Antitrust Litigation, In re Effexor Antitrust Litigation and In re Wellbutrin XL Antitrust Litigation
• Appointed lead counsel in MDL No. 2419: In re New England Compounding Pharmacy Inc. Products Liability, representing more than 700 victims who contracted fungal meningitis or other serious health problems as a result of receiving contaminated products produced by NECC, resulting in a $200 million settlement
• Lead counsel to the Prescription Access Litigation (PAL) project, the largest coalition of health care advocacy groups that fight illegal, loophole-based overpricing by pharmaceutical companies

Hon. Mitchell S. Goldberg, U.S. District Court, Eastern District of Pennsylvania, Philadelphia

Hon. Gene E.K. Pratter, U.S. District Court, Eastern District of Pennsylvania, Philadelphia

Jonathan Berman, Jones Day, Washington, DC

Jayne A. Goldstein, Shepherd, Finkelman, Miller & Shah, LLP, Fort Lauderdale, FL

Lindsay D. Breedlove, Pepper Hamilton LLP, Philadelphia

Mark S. Cheffo, Quinn Emanuel, Urquhart & Sullivan LLP, New York

Christopher T. Holding, Goodwin Procter LLP, Boston

Leslie E. John, Ballard Spahr LLP, Philadelphia

Jeffrey L. Kodroff, Spector Roseman Kodroff & Willis, P.C., Philadelphia

Kristen A. Johnson, Hagens Berman Sobol Shapiro LLP, Boston

Robert N. Kaplan, Kaplan Fox & Kilsheimer LLP, New York

Peter Kohn, Faruqi & Faruqi, Philadelphia

Arnold Levin, Levin, Sedran & Berman, , Philadelphia

Sarah Lieber, Vice President, Underwriting and Investment, Burford Capital LLC, New York

Christine C. Levin, Dechert LLP, Philadelphia

Jan P. Levine, Pepper Hamilton LLP, Philadelphia

Roberta D. Liebenberg, Fine, Kaplan and Black, R.P.C., Philadelphia

Joseph H. Meltzer, Kessler Topaz Meltzer & Check, LLP, Radnor, PA

Ellen Meriwether, Cafferty Clobes Meriwether & Sprengel LLP, Philadelphia

Linda P. Nussbaum, Nussbaum Law Group, P.C., New York

Sharon K. Robertson, Cohen Milstein Sellers & Toll PLLC, New York

Christopher A. Seeger, Seeger Weiss, LLP, New York

Laurence A. Schoen, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Boston

Stephen Shadowen, Hilliard & Shadowen LLP, Austin, TX

Peter St. Phillip, Lowey Dannenberg Cohen & Hart, P.C., White Plains, NY